Passage Bio, Inc. (PASG)
PASGNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$3.43
-0.5239 (-13.25%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $11.97m
- P/E
- –
- EPS, last 4 quarters
- $-11.32
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.29 to $20.00
- Average volume
- 21.2k
- Previous close
- $3.95
Earnings
next estimate $-2.43Next report
Sep 2025
+7.6%
Dec 2025
-86.3%
Mar 2026
-9.8%
Jun 2026
-10.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$8.65m | -$13.85m | -$8.25m | -$8.27m |
| Net income | -$7.75m | -$12.98m | -$7.56m | -$7.82m |
News
8 latest- Passage Bio, Inc. Stockholders Approve Merger Proposals, Reverse Stock Split of 1-for-2 to 1-for-10, and Name ChangeFintel · 4 days ago
- Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired RTTNews · Jun 26, 2026
- Passage Bio And Remix Therapeutics Enter All-Stock Merger Agreement; Stock Down RTTNews · Jun 25, 2026
- Oppenheimer Initiates Coverage of Passage Bio (PASG) with Outperform RecommendationFintel · Mar 31, 2026
- Passage Bio (PASG) Price Target Increased by 21.85% to 40.39Fintel · Dec 6, 2025
- PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates RTTNews · Nov 10, 2025
- Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a BetZacks · Sep 1, 2025
- Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to TradeZacks · Aug 15, 2025
The company
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- passagebio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.